In brief
In a recent announcement, President Trump revealed that EMD Serono will lower the price of Gonal-f, a crucial drug for in vitro fertilization (IVF). This comes alongside new federal guidelines that will allow companies to offer fertility benefits independently of major health insurance plans. While these initiatives are steps forward in making IVF more accessible, they don't fulfill Trump's earlier promise to provide free IVF treatments. The move includes developing another drug, Pergoveris, to expedite approval in the U.S. as part of ongoing efforts to support families seeking fertility treatments.
President Donald Trump announced that drugmaker EMD Serono has agreed to lower the cost of Gonal-f, a widely used fertility medication, as part of a deal with his administration. This announcement also included federal guidance that encourages businesses to offer fertility benefits alongside dental and vision plans, a move intended to make IVF more accessible to those facing infertility challenges.The guidance aims to support families by allowing employers to provide fertility related benefits separately from standard medical insurance. This initiative comes in light of Trump's executive order earlier this year aimed at reducing the costs associated with in vitro fertilization, which often burdens hopeful parents with expenses running into thousands of dollars across multiple treatment cycles.The new guidance and pricing plan are viewed as progress in the administration's ongoing commitment to assist families in building their families amid rising costs associated with fertility treatments. Trump indicated that Gonal-f and potentially another drug, Pergoveris, will be available at discounted rates on a government website, TrumpRx, allowing patients direct access to the drugs from manufacturers.While the administration's attempts to reduce costs have garnered praise, they lack the fulfillment of an earlier campaign promise made by Trump to make IVF free for all. This announcement builds on an evolving dialogue around reproductive health, especially in the context of broader shifts in legislation regarding reproductive rights.Experts, including Roger Shedlin, CEO of the fertility benefits firm WIN, expressed optimism over the administration’s latest moves, highlighting that any reduction in drug costs has the potential to significantly alleviate the overall financial burden on families undergoing IVF. Additionally, individuals like Corinn O’Brien have voiced how crucial these changes are for many families trying to conceive, affirming that even reduced costs are a welcome step, while full coverage would represent a major breakthrough in supporting family expansion efforts.
